Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...
Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- (March Bio), an emerging clinical stage biotechnology company committed to combating ...
This is compared to 83% ... Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough Designation July 10, 2024 — CAR-T cell therapy helps some with intractable lymphoma ...
Dr Matthew McKinney reflects on his first experience of treating DLBCL and highlights the advancements in emerging treatments ...
Dr Matthew McKinney reflects on the mentorship and diverse experiences that shaped his philosophy toward patient care and ...
The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...
Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...
The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback